Current and future therapies for hepatitis C virus infection

New England Journal of Medicine

Volumn 369, Issue 7, 2013, Pages 679-680

  Ozaras, Resat ^a   Yemisen, Mücahit ^a   Balkan, Ilker I ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; DRUG INFORMATION; DRUG LABELING; FOOD AND DRUG ADMINISTRATION;

EID: 84881467036     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1307589     Document Type: Letter

References (3)

1. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-17.
2. Highlights of prescribing information: Victrelis (boceprevir) capsules for oral use. Whitehouse Station, NJ: Merck (http://www.merck.com/product/usa/ pi-circulars/v/victrelis/victrelis-pi.pdf).
3. Summary of product characteristics: Victrelis. London: European Medicines Agency (http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/002332/WC500109786.pdf).